Balchem Corporation Reports 8.6% Revenue Growth in Q3 2026

Balchem Corporation reported a notable increase in financial performance for the third quarter and the first nine months of 2026, as detailed in its latest 10-Q filing. For the three months ended September 30, 2026, the company achieved net sales of $290.7 million, an increase of 8.6% from $267.6 million in the same period of 2025. The gross margin also improved, rising to $105.7 million, up 10.7% from $95.5 million year-over-year. Net earnings for the quarter reached $46.7 million, reflecting a 16% increase compared to $40.3 million in the prior year. For the nine-month period, net sales totaled $845.4 million, a 9.3% increase from $773.5 million, with net earnings rising to $131.6 million from $115.6 million.

The company's financial metrics indicate significant growth across its segments. The Human Nutrition & Health segment saw sales increase by 8.1% to $188.2 million, driven by higher sales in nutrients and food ingredients. The Animal Nutrition & Health segment reported an 11.7% increase in sales to $63 million, attributed to higher demand in both monogastric and ruminant markets. Specialty Products also experienced growth, with sales rising 4.5% to $37.3 million, primarily due to increased sales in performance gases.

Operationally, Balchem's total assets increased to $1.7 billion as of September 30, 2026, compared to $1.7 billion at the end of 2025. The company reported a decrease in current liabilities to $164.1 million from $176.4 million, while stockholders' equity rose to $1.3 billion from $1.3 billion. The company employed approximately 1,430 full-time employees as of the end of the quarter, reflecting stable labor market conditions that support its operational needs.

Strategically, Balchem has been active in managing its capital structure, including a recent amendment to its revolving credit facility, which increased the commitment amount from $550 million to $650 million and extended the maturity date to July 2023. The company also continued its stock repurchase program, buying back 443,747 shares during the nine months ended September 30, 2026, at an average price of $163.97 per share. Looking ahead, Balchem remains focused on pursuing growth opportunities, including potential acquisitions, while maintaining a strong balance sheet to support its operational and strategic initiatives.